Literature DB >> 20714105

Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis.

Dominic J Ciavatta1, Jiajin Yang, Gloria A Preston, Anshul K Badhwar, Hong Xiao, Peter Hewins, Carla M Nester, William F Pendergraft, Terry R Magnuson, J Charles Jennette, Ronald J Falk.   

Abstract

Antineutrophil cytoplasmic autoantibody (ANCA) causes vascular injury that leads to small-vessel vasculitis. Patients with ANCA aberrantly express neutrophil granule-encoding genes, including 2 that encode autoantigens: proteinase 3 (PR3) and myeloperoxidase (MPO). To uncover a potential transcriptional regulatory mechanism for PR3 and MPO disrupted in patients with ANCA vasculitis, we examined the PR3 and MPO loci in neutrophils from ANCA patients and healthy control individuals for epigenetic modifications associated with gene silencing. We found that levels of the chromatin modification H3K27me3, which is associated with gene silencing, were depleted at PR3 and MPO loci in ANCA patients compared with healthy controls. Interestingly, in both patients and controls, DNA was unmethylated at a CpG island in PR3, whereas in healthy controls, DNA was methylated at a CpG island in MPO. Consistent with decreased levels of H3K27me3, JMJD3, the demethylase specific for H3K27me3, was preferentially expressed in ANCA patients versus healthy controls. In addition, we describe a mechanism for recruiting the H3K27 methyltransferase enhancer of zeste homolog 2 (EZH2) to PR3 and MPO loci mediated by RUNX3. RUNX3 message was decreased in patients compared with healthy controls, and may also be under epigenetic control. DNA methylation was increased at the RUNX3 promoter in ANCA patients. These data indicate that epigenetic modifications associated with gene silencing are perturbed at ANCA autoantigen-encoding genes, potentially contributing to inappropriate expression of PR3 and MPO in ANCA patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714105      PMCID: PMC2929711          DOI: 10.1172/JCI40034

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Histone methyltransferase activity of a Drosophila Polycomb group repressor complex.

Authors:  Jürg Müller; Craig M Hart; Nicole J Francis; Marcus L Vargas; Aditya Sengupta; Brigitte Wild; Ellen L Miller; Michael B O'Connor; Robert E Kingston; Jeffrey A Simon
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

2.  Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons.

Authors:  Ken-ichi Inoue; Shigeru Ozaki; Takashi Shiga; Kosei Ito; Tomoyuki Masuda; Nobuo Okado; Tsutomu Iseda; Saburo Kawaguchi; Masaharu Ogawa; Suk-Chul Bae; Namiko Yamashita; Shigeyoshi Itohara; Norio Kudo; Yoshiaki Ito
Journal:  Nat Neurosci       Date:  2002-10       Impact factor: 24.884

Review 3.  Epigenetic gene silencing by Runx proteins.

Authors:  Ichiro Taniuchi; Dan R Littman
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

4.  Elongator interactions with nascent mRNA revealed by RNA immunoprecipitation.

Authors:  Christopher Gilbert; Arnold Kristjuhan; G Sebastiaan Winkler; Jesper Q Svejstrup
Journal:  Mol Cell       Date:  2004-05-21       Impact factor: 17.970

5.  Improved quantification of DNA methylation using methylation-sensitive restriction enzymes and real-time PCR.

Authors:  Ko Hashimoto; Shoichi Kokubun; Eiji Itoi; Helmtrud I Roach
Journal:  Epigenetics       Date:  2007-03-27       Impact factor: 4.528

Review 6.  Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides.

Authors:  Cees G M Kallenberg; Peter Heeringa; Coen A Stegeman
Journal:  Nat Clin Pract Rheumatol       Date:  2006-12

7.  Cytosine demethylation of the proteinase-3/myeloblastin primary granule protease gene during phagocyte development.

Authors:  M Lübbert; A Tobler; M Daskalakis
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

8.  Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.

Authors:  Ja-Lok Ku; Sung-Bum Kang; Young-Kyoung Shin; Hio Chung Kang; Sung-Hye Hong; Il-Jin Kim; Joo-Ho Shin; Inn-Oc Han; Jae-Gahb Park
Journal:  Oncogene       Date:  2004-09-02       Impact factor: 9.867

9.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

10.  Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.

Authors:  Satoshi Fujii; Kosei Ito; Yoshiaki Ito; Atsushi Ochiai
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

View more
  69 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 2.  Molecular mechanisms and potential functions of histone demethylases.

Authors:  Susanne Marije Kooistra; Kristian Helin
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

Review 3.  Epigenomics: the science of no-longer-junk DNA. Why study it in chronic kidney disease?

Authors:  Yi-An Ko; Katalin Susztak
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

4.  Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis.

Authors:  Elizabeth A McInnis; Anshul K Badhwar; Akhil Muthigi; Olivier M Lardinois; S Colby Allred; Jiajin Yang; Meghan E Free; J Charles Jennette; Gloria A Preston; Ronald J Falk; Dominic J Ciavatta
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

5.  [Epigentics in rheumatic diseases].

Authors:  A Jüngel; S Gay
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

Review 6.  Epigenetics and complementary proteins.

Authors:  D Ciavatta; R J Falk
Journal:  Clin Exp Immunol       Date:  2011-05       Impact factor: 4.330

7.  Genetically determined severity of anti-myeloperoxidase glomerulonephritis.

Authors:  Hong Xiao; Dominic Ciavatta; David L Aylor; Peiqi Hu; Fernando Pardo-Manuel de Villena; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

Review 8.  B cell-mediated pathogenesis of ANCA-mediated vasculitis.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

9.  A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

Authors:  T Kurz; M Weiner; C Skoglund; S Basnet; P Eriksson; M Segelmark
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

10.  CD14 expression is increased on monocytes in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis and correlates with the expression of ANCA autoantigens.

Authors:  R M Tarzi; J Liu; S Schneiter; N R Hill; T H Page; H T Cook; C D Pusey; K J Woollard
Journal:  Clin Exp Immunol       Date:  2015-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.